Telomerase activity and hTERT mRNA expression in glial tumors

International Journal of Oncology

Volumn 28, Issue 6, 2006, Pages 1555-1560

  Boldrini, L ^a   Pistolesi, S ^a   Gisfredi, S ^a   Ursino, S ^a   Ali G ^a   Pieracci, N ^a   Basolo, F ^a   Parenti, G ^a   Fontanini, Gabriella ^a  

^a UNIVERSITY OF PISA   (Italy)

Author keywords

Gliomas; hTERT mRNA; Telomerase activity

Indexed keywords

MESSENGER RNA; PRIMER DNA; TELOMERASE;

AGED; ARTICLE; ASTROCYTOMA; BRAIN TUMOR; GENETICS; GLIOBLASTOMA; GLIOMA; HUMAN; METABOLISM; MORTALITY; NUCLEOTIDE SEQUENCE; PROGNOSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SURVIVAL;

AGED; ASTROCYTOMA; BASE SEQUENCE; BRAIN NEOPLASMS; DNA PRIMERS; GLIOBLASTOMA; GLIOMA; HUMANS; PROGNOSIS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SURVIVAL ANALYSIS; TELOMERASE;

EID: 33747109928     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.28.6.1555     Document Type: Article

References (50)

1. Blackbun FH: Structure and function of telomeres. Nature 350: 569-573, 1991.
2. Greider CW: Telomere length regulation. Annu Rev Biochem 65: 337-365, 1996.
3. McEachern MJ, Krauskopf and Blackburn EH: Telomeres and their control. Annu Rev Genet 34: 331-358, 2000.
4. Shay JW and Bacchetti S: A survey of telomerase activity in human cancer. Eur J Cancer 33: 787-791, 1997.
5. Chadeneau C, Hay K, Hirte HW, Gallinger S and Bacchetti S: Telomerase activity associated with acquisition of malignancy in human colorectal cancer. Cancer Res 55: 2533-2536, 1995.
6. Tahara H, Nakanishi T, Kitamoto M, et al: Telomerase activity in human liver tissues: comparison between chronic liver disease and hepatocellular carcinomas. Cancer Res 55: 2734-2736, 1995.
7. Hiyama K, Hiyama E, Ishioka S, et al: Telomerase activity in small-cell and non-small-cell lung cancers. J Natl Cancer Inst 87: 895-902, 1995.
8. Hiyama E, Okayama T, Tatsumoto N, et al: Telomerase activity in gastric cancer. Cancer Res 55: 3258-3262, 1995.
9. Sommerfeld HJ, Meeker AK, Piatyszek MA, Bova GS, Shay JW and Coffey DS: Telomerase activity: a prevalent marker of malignant human prostate tissue. Cancer Res 56: 218-222, 1996.
10. Hiyama E, Gollahan L, Kataoka T, et al: Telomerase activity in human breast tumors. J Natl Cancer Inst 88: 116-122, 1996. (Pubitemid 26020100)
11. Sallinen P, Miettinem H, Sallinem SL, Haapasalo H, Helin H and Kononem J: Increased expression of telomerase RNA component is associated with increased cell proliferation in human astrocytomas. Am J Pathol 150: 1159-1164, 1997.
12. Falchetti ML, Pallini R, Larocca LM, Verna R and D'Ambrosio E: Telomerase expression in intracranial tumors: prognostic potential for malignant gliomas and meningiomas. J Clin Pathol 52: 234-236, 1999.
13. Grzybicki DM and Moore SA: Implications of prognostic markers in brain tumors. Clin Lab Med 19: 833-847, 1999.
14. Chen HJ, Liang CL, Kang L, Lin JW and Cho CL: Implication of telomerase activity and alterations of telomere length in the histologic characteristics of intracranial meningiomas. Cancer 89: 2092-2098, 2000.
15. Cabuy E and De Ridder L: Telomerase activity and expression of telomerase reverse transcriptase correlated with cell proliferation in meningiomas and brain tumors in vivo. Virchows Arch 439: 176-184, 2001.
16. Boldrini L, Pistolesi S, Gisfredi S, et al: Telomerase in intracranial meningiomas. Int J Mol Med 12: 943-947, 2003.
17. Langford LA, Piatyszek MA, Xu R, Schold SC Jr and Shay JW: Telomerase activity in human brain tumors. Lancet 346: 1267-1268, 1995.
18. De Masters BK, Markham N, Lillehei KO and Shroyer KP: Differential telomerase expression in human primary intracranial tumors. Am J Pathol 107: 548-554, 1997.
19. Nakatani K, Yoshimi N, Mori H, Yoshimura S, Sakai H, Shinoda J and Sakai N: The significant role of telomerase activity in human brain tumor. Cancer 80: 471-476, 1997.
20. Kleinschmidt BK-De Masters, Hashizumi TL, Sze CI, Lillehei KO, Shroyer AL and Shroyer KR: Telomerase expression shows differences across multiple regions of oligodendroglioma versus high grade astrocytomas but shows correlation with Mib-1 labelling. J Clin Pathol 51: 284-293, 1998.
21. Hiyama E, Hiyama K, Yokoyama T, Matsuura Y, Piatyszek MA and Shay JW: Correlating telomerase activity levels with human neuroblastoma outcomes. Nat Med 1: 249-255, 1995.
22. Fukushima T, Yoshino A, Katayama Y, Watanabe T, Kusama K and Moro I: Prediction of clinical course of diffusely infiltrating astrocytomas from telomerase expression and quantitated activity level. Cancer Lett 187: 191-198, 2002.
23. Huang F, Kanno H, Yamamoto I, Lin Y and Kubota Y: Correlation of clinical features and telomerase activity in human gliomas. J Neurooncol 43: 137-142, 1999.
24. Tchirkov A, Rolhion C, Kemeny J-L, et al: Clinical implication of quantitative real-time RT-PCR analysis of hTERT gene expression in human gliomas. Br J Cancer 88: 516-520, 2003.
25. Louis DN: Meningiomas. In: Pathology and Genetics of tumors of the Nervous System. Kleihues P and Cavanee WK (eds). IARC press, Lyon, pp176-184, 2000.
26. Kleihues P, Louis DN, Scheithauer BW, Rorke LB, Reifenberger G, Burger PC and Cavanee WK: The WHO classification of tumors of the nervous system. J Neuropathol Exp Neurol 61: 215-225, 2002.
27. Wright WE, Shay JW and Piatyszek MA: Modifications of a telomeric repeat amplification protocol (TRAP) result in increased reliability, linearity and sensitivity. Nucleic Acids Res 23: 3794-3795, 1995.
28. Ulaner GA, Hu J-F, Vu TH, Giudice LC and Hoffman AR: Telomerase activity in human development is regulated by human telomerase reverse transcriptase (hTERT) transcription and by alternate splicing of hTERT transcripts. Cancer Res 58: 4168-4172, 1998.
29. Wizigmann-Voos S, Breier G, Risau W and Plate KH: Upregulation of vascular endothelial growth factor and its receptors in von Hippel-Lindau disease-associated and sporadic hemangioblastomas. Cancer Res 55: 1358-1364, 1995.
30. Holt SE, Aisner DL, Shay JW and Wright WE: Lack of cell cycle regulation of telomerase activity in human cells. Proc Natl Acad Sci USA 94: 10687-10692, 1997.
31. Blasco MA, Rizen M, Greider CW, et al: Differential regulation of telomerase activity and telomerase RNA during multi-stage tumorigenesis. Nat Genet 12: 200-204, 1996.
32. Kim NW, Piatyszek MA, Prowse KR, et al: Specific association of human telomerase activity with immortal cells and cancer. Science 266: 2011-2015, 1994.
33. Morii K, Tanaka R, Onda K, Tsumanuma I and Yoshimura J: Expression of telomerase RNA, telomerase activity, and telomere length in human gliomas. Biochem Biophys Res Commun 239: 830-834, 1997.
34. Chong EY, Lam PY, Poon WS and Ng HK: Telomerase expression in gliomas including the non-astrocytic tumors. Hum Pathol 29: 599-603, 1998.
35. Hiraga S, Ohnishi T, Izumoto S, Miyahara E, Kanemura Y, Matsumura H and Arita N: Telomerase activity and alterations in telomere length in human brain tumor. Cancer Res 58: 2117-2125, 1998.
36. Simon M, Park T-W, Leuenroth S, Hans VHJ, Loning T and Schramm J: Telomerase activity and expression of the telomerase catalytic subunit, hTERT, in meningioma progression. J Neurosurg 92: 832-840, 2000.
37. Le S, Zhu JJ, Anthony DC, Greider CW and Black PM: Telomerase activity in human gliomas. Neurosurgery 42: 1120-1125, 1998.
38. Sano T, Asai A, Mishima K, Fujimaki T and Kirino T: Telomerase activity in 144 brain tumors. Br J Cancer 77: 1633-1637, 1998.
39. Hakin-Smith V, Jellinek DA, Levy D, et al: Alternative lengthening of telomeres and survival in patients with glioblastoma multiform. Lancet 361: 836-838, 2003.
40. Ozbek N, Cakir S, Gursel B and Meydan D: Prognostic significance of seizure in patients with glioblastoma multiform. Neurol India 52: 76-78, 2004.
41. Batchelor TT, Betensky RA, Esposito JM, et al: Age-dependent prognostic effects of genetic alterations in glioblastoma. Clin Cancer Res 10: 228-233, 2004.
42. Boldrini L, Faviana P, Gisfredi S, et al: Evaluation of telomerase mRNA (hTERT) in colon cancer. Int J Oncol 21: 493-449, 2002.
43. Boldrini L, Loggini B, Gisfredi S, et al: Evaluation of telomerase in non-melanoma skin cancer. Int J Mol Med 11: 607-611, 2003.
44. Xu D, Gruber A, Bjorkholm M, Peterson C and Pisa P: Suppression of telomerase reverse transcriptase (hTERT) expression in differentiated HL-60 cells: regulatory mechanisms. Br J Cancer 80: 1156-1161, 1999.
45. Bachand F, Triki I and Autexier C: Human telomerase RNA-protein interactions. Nucleic Acids Res 29: 3385-3393, 2001.
46. Ford LP, Suh JM, Wright WE and Shay JW: Heterogeneous nuclear ribonucleoproteins C1 and C2 associate with the RNA component of human telomerase. Mol Cell Biol 20: 9084-9091, 2000.
47. Yi X, Shay JW and Wright WE: Quantitation of telomerase components and hTERT mRNA splicing patterns in immortal human cells. Nucleic Acids Res 29: 4818-4823, 2001.
48. Ozawa T, Gryaznov SM, Hu LJ, et al: Antitumor effects of specific telomerase inhibitor GRN163 in human glioblastoma xenografts. Neurooncology 6: 218-226, 2004.
49. Takeuchi H, Kanzawa T, Kondo Y, Komata T, Hirohata S, Kyo S and Kondo S: Combination of caspase transfer using the human telomerase reverse transcriptase promoter and conventional therapies for malignant glioma cells. Int J Oncol 25: 57-63, 2004.
50. Strakova N, Ehrmann J, Dzubak P, Bouchal J and Kolar Z: The synthetic ligand of peroxisome proliferator-activated receptor-gamma ciglitazone affects human glioblastoma cell lines. J Pharmacol Exp Ther 309: 1239-1247, 2004.